Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy

Investigational New Drugs

Volumn 15, Issue 1, 1997, Pages 15-28

  Fox, Stephen B ^a   Harris, Adrian L ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Histology; Methods; Prognosis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CELL ADHESION MOLECULE; PROTEINASE; TUMOR MARKER;

ANGIOGENESIS; CLINICAL TRIAL; HUMAN; IMAGE ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR; TUMOR VASCULARIZATION;

ANTIBODIES; ANTIGEN-ANTIBODY REACTIONS; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUGS, INVESTIGATIONAL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE HYDROLASES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030920373     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005714527315     Document Type: Review

References (174)

1. Folkman J: Tumour angiogenesis: Therapeutic implications. N. Engl J Med 285:82-86, 1971
2. Brem S, Cotran R, Folkman J: Tumor angiogenesis: a quantitative method for histological grading. J Natl Cancer Inst 48:347-356, 1972
3. Mlynek M, van Beunigen D, Leder L-D, et al.: Measurement of the grade of vascularisation in histological tumor tissue sections. Br J Cancer 52:945-948, 1985
4. Svrivastava A, Laidler P, Davies R, et al.: The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 thick) skin melanoma. Am J Pathol 133:419-423, 1988
5. Porschen R, Classen S, Piontek M, et al.: Vascularization of carcinomas of the esophagus and its correlation with tumor proliferation. Cancer Res 54:587-591, 1994
6. Weidner N, Semple JP, Welch WR, et al.: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
7. Weidner N, Folkman J, Pozza F, et al.: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma (see comments). J Natl Cancer Inst 84:1875-1887, 1992
8. Weidner N, Carroll PR, Flax J, et al.: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409, 1993
9. Bosari S, Lee AK, DeLellis RA, et al.: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992
10. Macchiarini P, Fontanini G, Hardin MJ, et al.: Relation of neovascularisation to metastasis of non-small cell lung cancer. Lancet 340:145-146, 1992
11. Macchiarini P, Fontanini G, Dulmet E, et al.: Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thor Surg 57:1534-1539, 1994
12. Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371-374, 1993
13. Wakui S, Furusato M, Itoh T, et al.: Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 168:257-262, 1992
14. Horak ER, Leek R, Klenk N, et al.: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992
15. Barnhill RL, Mihm MJ, Ceballos PI: Angiogenesis and regressing cutaneous malignant melanoma (letter). Lancet 339:991-992, 1992
16. Bigler S, Deering R, Brawer M: Comparisons of microscopic vascularity in benign and malignant prostate tissue. Human Pathol 24:220-226, 1993
17. Ogawa Y, Chung Y, Nakata B, et al.: An evaluation of angiogenesis in breast cancer with factor VIII related antigen staining. Proc Am Asoc Cancer Res 35:186 (abstr 1113), 1994
18. Bundred N, Bowcott M, Walls J, et al.: Angiogenesis in breast cancer predicts node metastasis and survival. Br J Surgery 81:768 (Abstract), 1994
19. Dickinson AJ, Fox SB, Persad RA, et al.: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74:762-766, 1994
20. Jaeger T, Weidner N, Chew K, et al.: Tumor angiogenesis predicts lymph node metastasis in invasive bladder cancer. Proc Am Assoc Cancer Res 35:66 (abstract 394), 1994
21. Li V, Folkerth R, Watanabe H, et al.: Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 344:82-86, 1994
22. Olivarez D, Ulbright T, DeRiese W, et al.: Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res 54:2800-2802, 1994
23. Vesalainen S, Lipponen P, Talja M, et al.: Tumor vascularity and basement membrane structure as prognostic factors in Tl-2MO prostatic adenocarcinoma. Anticancer Res 14:709-714, 1994
24. Simpson J, Ahn C, Battifora H, et al.: Vascular surface area as a prognostic indicator in invasive breast carcinoma. Lab Invest 70:22A (abstract), 1994
25. Smith-McCune K, Weidner N: Demonstration and characterization of the angiogenic properties of cervival dysplasia. Cancer Res 54:800-804, 1994
26. Brawer MK, Deering RE, Brown M, et al.: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73:678-687, 1994
27. Albo D, Granick M, Jhala N, et al.: The relationship of angiogenesis to biological activity in human squamous cell carcinomas of the head and neck. Ann Plast Surg 32:558-594, 1994
28. Wiggins DL, Granai CO, Steinhoff MM, et al.: Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol 56:353-356, 1995
29. Van HM, Knox WF, Dhesi SS, et al.: Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer, 1993
30. Hall NR, Fish DE, Hunt N, et al.: Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1:223-229, 1992
31. Sightler H, Borowsky A, Dupont W, et al.: Evaluation of tumor angiogenesis as a prognostic marker in breast cancer. Lab Invest 70:22A (abstract), 1994
32. Rutgers JL, Mattox TF, Vargas MP: Angiogenesis in uterine cervical squamous cell carcinoma. Int J Gynecol Pathol 14:114-118, 1995
33. Ohsawa M, Tomita Y, Kuratsu S, et al.: Angiogenesis in malignant fibrous histiocytoma. Oncology 52:51-54, 1995
34. Barnhill R, Busam K, Berwick M, et al.: Tumour vascularity is not a prognostic factor for cutaneous melanoma. Lancet 344:1237-1238, 1994
35. Axelsson K, Ljung B, Moore II D, et al.: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87, 1995
36. Protopapa E, Delides GS, Revesz L: Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy. Eur J Cancer, 1993
37. McCarthy SA, Kuzu I, Gatter KC, et al.: Heterogeneity of the endothelial cell and its role in organ preference of tumor metastasis. Trends Pharmacol Sci 12:462-467, 1991
38. Kuzu I, Bicknell R, Harris AL, et al.: Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumors. J Clin Pathol 45:143-148, 1992
39. Parums D, Cordell J, Micklem K, et al.: JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752-757, 1990
40. Fox SB, Leek R, Smith K, et al.: Tumor angiogenesis in node negative breast carcinomas-relationship to epidermal growth factor receptor and survival. Breast Cancer Res Treat 29:109-116, 1994
41. Ottinetti A, Sapino A: Morphometric evaluation of microvessels surrounding hyperplastic and neoplastic mammary lesions. Breast Cancer Res Treat 11:241-248, 1988
42. Sahin A, Sneige N, Singletary E, et al.: Tumor angiogenesis detected by Factor-VIII immunostaining in node-negative breast carcinoma (NNBC): a possible predictor of distant metastasis. Mod Pathol 5:17A (abstract), 1992
43. Weidner N, Gasparini G: Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients. Breast Cancer Res Treat 29:97-108, 1994
44. Carnochan P, Briggs JC, Westbury G, et al.: The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness. Br J Cancer 64:102-107, 1991
45. Barnhill RL, Fandrey K, Levy MA, et al.: Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 67:331-337, 1992
46. Visscher D, Smilanetz S, Drozdowicz S, et al.: Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal Quant Cytol 15:88-92, 1993
47. Visscher D, DeMattia F, Boman S: Technical factors affecting image morphometric microvessel density counts in breast carcinomas. Lab Invest 70:168A (abstract), 1994
48. Burrows FJ, Thorpe PE: Vascular targeting - a new approach to the therapy of solid tumors. Pharmacol Ther 64:155-174, 1994
49. Weidner N, Gasparini G, Bevilacqua P, et al.: Tumor microvessel density, p53 expression, and tumor size area relevant prognostic markers in node negative breast carcinomas. Lab Invest 70:A24 (abstract), 1994
50. Barbareschi M, Weidner N, Gasparini G, et al.: Microvessel quantitation in breast carcinomas. Appl Immunochem 3:75-84, 1995
51. Fox SB, Leek RD, Weekes. M P, et al.: Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count and computer image analysis. J Pathol in press, 1995
52. Furusato M, Wakui S, Sasaki H, et al.: Tumour angiogenesis in latent prostatic carcinoma. Br J Cancer 70:1244-1246, 1994
53. Williams JK, Carlson GW, Cohen C, et al.: Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am J Surg 168:373-380, 1994
54. Wesseling P, Vandersteenhoven JJ, Downey BT, et al.: Cellular components of microvascular proliferation in human glial and metastatic brain neoplasms. A light microscopic and immunohistochemical study of formalin-fixed, routinely processed material. Acta Neuropathol (Berl) 85:508-514, 1993
55. Charpin C, Devictor B, Bergeret D, et al.: CD31 Quantitative immunocytochemical assays in breast carcinomas. Am J Clin Pathol 103:443-448, 1995
56. Chalkley H: Method for the quantative morphological analysis of tissues. J Nat Cancer Inst 4:47-53, 1943
57. Guinebretiere JM, Le MG, Gavoille A, et al.: Angiogenesis and risk of breast cancer in women with fibrocystic disease (letter). J Natl Cancer Inst 86:635-636, 1994
58. Paweletz N, Knierim M: Tumor-related angiogenesis. Crit Rev Oncol Hematol 9:197-242, 1989
59. Blood CH, Zetter BR: Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1032:89-118, 1990
60. Bicknell R, Harris AL: Novel growth regulatory factors and tumor angiogenesis. Eur J Cancer 27:781-785, 1991
61. Takahashi Y, Kitadai Y, Bucana CD, et al.: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res 55:3964-3968, 1995
62. Brown LF, Berse B, Jackman RW, et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91, 1995
63. Moghaddam A, Zhang HT, Fan TP, et al.: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:998-1002, 1995
64. Anandappa SY, Winstanley JH, Leinster S, et al. : Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Br J Cancer 69:772-776, 1994
65. Reynolds K, Farzaneh F, Collins WP, et al.: Correlation of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst. In press, 1994
66. Garver RJ, Radford DM, Donis KH, et al.: Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 74:1584-1590, 1994
67. Janot F, el Nagar NA, Morrison RS, et al.: Expression of basic fibroblast growth factor in squamous cell carcinoma of the head and neck is associated with degree of histologic differentiation. Int J Cancer 64:117-123, 1995
68. Gomm JJ, Smith J, Ryall GK, et al.: Localisation of basic fibroblast growth factor and transforming growth factor bl in the human mammary gland. Cancer Res 51:4685-4692, 1991
69. Zarnegar R, DeFrances MC: Expression of HGF-SF in normal and malignant human tissues. Exs 65:181-199, 1993
70. Daa T, Kodama M, Kashima K, et al.: Identification of basic fibroblast growth factor in papillary carcinoma of the thyroid. Acta Pathol Jpn 43:582-589, 1993
71. Wong SY, Purdie AT, Han P: Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. Am J Pathol 140:1473-1482, 1992
72. Schultz-Hector S, Haghayegh S: B-Fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res 53:1444-1449, 1993
73. Alvarez JA, Baird A, Tatum A, et al.: Localisation of basic fibroblast growth factor and vascular endothelial cell growth factor in human glial neoplasms. Mod Pathol 5:303-307, 1992
74. Guidi A, Abu-Jawdeh G, Berse B, et al.: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Instit 87:1237-1245, 1995
75. Zagzag D, Brem S, Robert F: Neovascularization and tumor growth in the rabbit brain. A model for experimental studies of angiogenesis and the blood-brain barrier. Am J Pathol 131:361-372, 1988
76. Visscher DW, DeMattia F, Ottosen S, et al.: Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Mod Pathol 8:665-670, 1995
77. O'Brien T, Cranston D, Fuggle S, et al.: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55:510-513, 1995
78. Toi M, Hoshina S, Takayanagi T, et al.: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85:1045-1049, 1994
79. Toi M, Hoshina S, Taniguchi T, et al.: Expression of platelet derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer 64:79-82, 1995
80. Fox SB, Westwood M, Moghaddam A, et al.: The angiogenic factor platelet derived endothelial cell growth factor/thymidine phosphorylase is upregulated in breast cancer epithelium and endothelium. Br J Cancer (in press), 1995
81. Fujimoto K, Ichimori Y, Kakizoe T, et al.: Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Comm 180:386-392, 1991
82. Kondo S, Asano M, Matsuo K, et al.: Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1221:211-214, 1994
83. Nguyen M, Watanabe H, Budson AE, et al.: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 85:241-242, 1993
84. Nguyen M, Watanabe H, Budson AE, et al.: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers (see comments). J Natl Cancer Inst 86:356-361, 1994
85. O'Brien T, Smith K, Cranston D, et al.: Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Br J Urol 76:311-314, 1995
86. Kendall RL, Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705-10709, 1993
87. Blann AD, McCollum CN: Circulating endothelial-cell leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 72:151-154, 1994
88. Frater-Schroder M, Risau W, Hallmann R, et al.: Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 84:5277-5281, 1987
89. Schweigerer L, Malerstein B, Gospodarowicz D: Tumor necrosis factor inhibits the proliferation of cultured capillary endothelial cells. Biochem Biophys Res Commun 143:997-1004, 1987
90. Pepper M, Montesano R: Proteolytic balance and capilary morphogenesis. Cell Differentiation and Development 32:319-328, 1990
91. Fisher C, Gilbertson BS, Powers EA, et al.: Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 162:499-510, 1994
92. Kristensen P, Larsson L, Nielsen L, et al.: Human endothelial cells contain one type of plasminogen activator. FEBS Lett 168:33-37, 1994
93. Larsson L, Skriver L, Nielsen J, et al.: Distribution of urokinase-type activator immunoreactivity in the mouse. J Cell Biol 98:894-903, 1984
94. Pepper MS, Ferrara N, Orci L, et al.: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181:902-906, 1991
95. Pepper MS, Belin D, Montesano R, et al.: Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 111:743-755, 1990
96. Pepper MS, Ferrara N, Orci L, et al.: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824-831, 1992
97. Grondahl HJ, Christensen U, Rosenquist C, et al.: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521, 1993
98. Janicke F, Schmitt M, Pache L, et al.: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993
99. Foekens JA, Schmitt M, van PW, et al.: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105, 1992
100. Duffy MJ, Reilly D, O'Sullivan C, et al.: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827-6829, 1990
101. Schmitt M, Janicke F, Moniwa N, et al.: Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 373:611-622, 1992
102. Spyratos F, Martin PM, Hacene K, et al.: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266-1272, 1992
103. Sumiyoshi K, Serizawa K, Urano T, et al.: Plasminogen activator system in human breast cancer. Int J Cancer 50:345-348, 1992
104. Ganesh S, Sier CFM, Heerding MM, et al. : Urokinase receptor and colorectal cancer survival. Lancet 344:401-402, 1994
105. Fox SB, Stuart N, Smith K, et al.: High levels of uPA and PAI-1 are associated with highly angiogenic breast carcinomas. J Pathol 170(suppl):388A, 1993
106. Nguyen M, Strubel NA, Bischoff J: A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 365:267-269, 1993
107. Kaplanski G, Farnarier C, Benoliel A, et al.: A novel role for E- and P-selectins: shape of endothelial cell monolayers. J Cell Sci 107:2449-2457, 1994
108. Koch A, Halloran MM, Haskell CJ, et al.: Angiogenesismediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376:517-519, 1995
109. Fox SB, Turner G, Gatter K, et al.: The increased expression of adhesion molecules ICAM-3, E and P selectin on breast cancer endothelium. J Pathol in press, 1995
110. Zocchi MR, Poggi A: Lymphocyte-endothelial cell adhesion molecules at the primary tumor site in human lung and renal cell carcinomas (letter). J Natl Cancer Inst 85:246-247, 1993
111. Fox SB, Gatter KC, Bicknell R, et al.: Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 53:9161-9163, 1993
112. Dvorak HF: Thrombosis and cancer. Hum Pathol 18:275-284, 1987
113. PalabricaT, LobbR, Furie BC, et al.: Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359:848-851, 1992
114. Senger DR, Van DWL, Brown LF, et al. : Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303-324, 1993
115. Leavesley DI, Schwartz MA, Rosenfeld M, et al.: Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 121:163-170, 1993
116. Gamble JR, Matthias LJ, Meyer G, et al.: Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 121:931-943, 1993
117. Davis CM, Danehower SC, Laurenza A, et al.: Identification of a role of the vitronectin receptor and protein kinase C in the induction of endothelial cell vascular formation. J Cell Biochem 51:206-218, 1993
118. Bauer J, Margolis M, Schreiner C, et al.: In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins, and integrins. J Cell Physiol 153:437-449, 1992
119. Jackson CJ, Knop A, Giles I, et al.: VLA-2 mediates the interaction of collagen with endothelium during in vitro vascular tube formation. Cell Biol Int 18:859-867, 1994
120. Luscinskas FW, Lawler J: Integrins as dynamic regulators of vascular function. Faseb J 8:929-938, 1994
121. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571, 1994
122. Brooks PC, Montgomery AM, Rosenfeld M, et al.: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164, 1994
123. v blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-1822, 1995
124. Iozzo RV: Tumor stroma as a regulator of neoplastic behaviour. Lab Invest 73:157-160, 1995
125. Lochter A, Bissell MJ: Involvement of extracellular matrix constituents in breast cancer. Cancer Biol 6:165-173, 1995
126. Schadendorf D, Heidel J, Gawlik C, et al.: Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 87:366-371, 1995
127. Kageshita T, Yoshii A, Kimura T, et al.: Clinical relevance of ICAM-1 expression in prmary lesions and serum of patients with malignant melanoma. Cancer Res 53:4927-4932, 1993
128. Banks RE, Gearing AJ, Hemingway IK, et al.: Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 68:122-124, 1993
129. Warren B : The vascular morphology of tumors. In: Peterson H (ed). Tumor Blood Circulation Boca Raton, Fla: CRC Press, 1979, pp 1-47
130. Paku S, Lapis K: Morphological aspects of angiogenesis in experimental liver metastases. Am J Pathol 143:926-936, 1993
131. Lauk S, Zietman A, Skates S, et al.: Comparative morphometric study of tumor vasculature in human squamous cell carcinomas and their xenotransplants in athymic nude mice. Cancer Res 49:4557-4561, 1989
132. Smolle J, Soyer HP, Hofmann-Wellenhof, et al.: Vascular archictecture of melanocytic skin tumors. Path Res Pract 185:740-745, 1989
133. Cockerell CJ, Sonnier G, Kelly L, et al.: Comparative analysis of neovascularisation in primary cutaneous melanoma and Spitz nevus. Am J Dermatopathol 16:9-13, 1994
134. Folberg R, Rummelt V, Ginderdeuren R-V, et al.: The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100:1389-1398, 1993
135. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449-6465, 1989
136. Jain RK: Barriers to drug delivery in solid tumors. Sci Am 271:58-65, 1994
137. Jain RK: Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9:253-266, 1990
138. Mitchell BS, Schumacher U, Kaiserling E: Are tumors innervated? Immunohistological investigations using antibodies against the neuronal marker protein gene product 9.5 (PGP 9.5) in benign, malignant and experimental tumors. Tumour Biol 15:269-274, 1994
139. Nystrom C, Forssman L, Roos B: Myometrial blood flow studies in carcinoma of the corpus uteri. Acta Radiol Ther 8:193-198, 1969
140. Frouge C, Guinbretiere J, Contesso G, et al.: Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. Invest Radiol 29:1043-1049, 1994
141. Lee WJ, Chu JS, Houng SJ, et al.: Breast cancer angiogenesis: a quantitative morphologic and Doppler imaging study. Ann Surg Oncol 2:246-251, 1995
142. Antonic J, Rakar S: Colour and pulsed doppler US and tumor marker CA125 in differentiation between benign and malignant ovarian masses. Anticancer Res 15:1527-1532, 1995
143. Wu CC, Lee CN, Chen TM, et al.: Incremental angiogenesis assessed by color Doppler ultrasound in the tumorigenesis of ovarian neoplasms. Cancer 73:1251-1256, 1994
144. Toi M, Inada K, Suzuki H, et al.: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36:193-204, 1995
145. OgawaY, ChungY, Nakata B, et al.: Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. Br J Cancer 71:1297-1301, 1995
146. Gasparini G, Weidner N, Bevilacqua P, et al.: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma (see comments). J Clin Oncol 12:454-466, 1994
147. Lipponen P, Ji H, Aaltomaa S, et al.: Tumour vascularity and basement membrane structure in breast cancer as related to tumor histology and prognosis. J Cancer Res Clin Oncol 120:645-650, 1994
148. Palczak R, Splawinski J: Angiogenic activity and neovascularization in adenocarcinoma of endometrium. Int J Gynaecol Obstet 29:343-357, 1989
149. Hollingsworth HC, Kohn EC, Steinberg SM, et al.: Tumor angiogenesis in advanced stage ovarian carcinoma (see comments). Am J Pathol 147:33-41, 1995
150. Hall MC, Troncoso P, Pollack A, et al. : Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 44:869-875, 1994
151. Jaeger T, Weidner N, Chew K, et al.: Tumor angiogenesis correlates with lymph node metastasis in invasive bladder cancer. J Urol 154:69-71, 1995
152. Giatromanolaki A, Koukourakis, O'Byrne K, et al.: Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol in press, 1995
153. Maeda K, Chung YS, Takatsuka S, et al.: Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 13:477-481, 1995
154. Saclarides TJ, Speziale NJ, Drab E, etal.: Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 37:921-926, 1994
155. Klijanienko J, El-Naggar A, de Braud F, et al.: Tumor vascularisation, mitotic index, histopathological grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. Cancer 75:1649-1656, 1995
156. Leedy DA, Trune DR, Kronz JD, et al.: Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue. Otolaryngol Head Neck Surg 111:417-422, 1994
157. Gasparini G, Weidner N, Maluta S, et al.: Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 55:739-744, 1993
158. Brem SS, M. JH, Gullino PM: Angiogenesis as a marker of pre-neoplastic lesions of the human breast. Cancer 41:239-248, 1978
159. Jensen HM, Chen I, DeVault MR, et al.: Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science 218:293-295, 1982
160. Guidi A, Fischer L, Harris J, et al.: Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86:614-619, 1994
161. Engels K, Fox SB, Gatter KC, et al.: Angiogenesis in ductal carcinoma in situ. J Pathol, 1995
162. Montironi R, Galluzzi C, Diamanti L, et al.: Prostatic intraepithelial neoplasia. Qualitative and qualitative analysis of the blood capillary architecture. Path Res Pract 189:542-548, 1993
163. Deering RE, Bigler SA, Brown M, et al.: Microvascularity in benign prostatic hyperplasia. Prostate 26:111-115, 1995
164. Macaulay VM, Fox SB, Zhang H, et al.: Breast cancer angiogenesis and tamoxifen resistence. Endocr Rel Cancer 2:1-8, 1995
165. O'Reilly MS, Holmgren L, Shing Y, et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma (see comments). Cell 79:315-328, 1994
166. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 13:765-782, 1995
167. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702-6704, 1992
168. Johnson PW, Burchill SA, Selby PJ: The molecular detection of circulating tumor cells. Br J Cancer 72:268-276, 1995
169. Larsen NS: Angiogenesis research yields new approaches to cancer treatment and prognosis (news). J Natl Cancer Inst 85:1629-1630, 1993
170. Wang JM, Kumar S, Pye D, et al.: A monoclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues. Int J Cancer 54:363-370, 1993
171. Rettig WJ, Garin CP, Healey JH, et al.: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89:10832-10836, 1992
172. Hagemeier HH, Vollmer E, Goerdt S, et al.: A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues. Int J Cancer 38:481-488, 1986
173. Schlingemann RO, Dingjan GM, Emeis JJ, et al.: Monoclonal antibody PAL-E specific for endothelium. Lab Invest 52:71-76, 1985
174. Koch AE, Nickoloff BJ, Holgersson J, et al.: 4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis. Am J Pathol 144:244-259, 1994